WilmerHale Represents Alcresta Therapeutics in Acquisition by Linden Capital Partners 

WilmerHale Represents Alcresta Therapeutics in Acquisition by Linden Capital Partners 

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Offering a sophisticated, full-service solution to private equity sponsors and entrepreneurs, from initial investment to exit.

On March 12, 2024, Linden Capital Partners, a private equity firm focused exclusively on the healthcare industry, announced the completion of its acquisition of Alcresta Therapeutics, a leader in commercializing novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Alcresta recently announced 510(k) clearance of its next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration. The next-generation RELiZORB device was developed to address the enteral nutrition needs of a wider population of patients living with rare diseases and is expected to launch in Q2 2024.

The WilmerHale team representing Alcresta was led by Hal Leibowitz, Caroline Dotolo, J.C. Minko, Taylor Mielnicki, Molly Nelson, and Meghan McDuff, with support from Kim Wethly, Scott Kilgore, Justin Ochs, Chalyse Robinson, Julie Hogan Rodgers, Steven Barrett, Kirk Nahra, Doug Burton, Bruce Manheim, Hartmut Schneider, Barry Hurewitz, David Gold, Atul Jain, Alex Dean, Simona Altshuler, and Carla Gilbertson.  

 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel